Trials / Unknown
UnknownNCT01002092
A Study of Endostar Combined With Chemotherapy for Treatment of Osteosarcoma
A Randomized, Controlled Multicenter Trial of Endostar Combined With Chemotherapy for Treatment of Osteosarcoma
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 160 (estimated)
- Sponsor
- Shandong Simcere-Medgenn Bio-pharmaceutical Co., Ltd · Industry
- Sex
- All
- Age
- 12 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
Purpose: This study will assess the safety and efficacy of Endostar combined with chemotherapy in osteosarcoma patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Chemotherapy | Week 1 day 1 MTX 8 g/m2; Week 3 day 1-2 CDP 100-120 mg/m2 day 1 ADM/THP 60 mg/m2; Week 5 day 1-6 IFO 2 g/day; Week 7 rest; Week 8 surgery; Two weeks after the surgery repeat the chemotherapy cycle 3 times (6 weeks per cycle). |
| DRUG | Endostar | In each cycle, Week 1-2 day 1-14 endostar 7.5 mg/m2/day; Week 5-6 day 1-14 endostar 7.5 mg/m2/day |
Timeline
- Start date
- 2009-02-01
- Primary completion
- 2014-12-01
- Completion
- 2014-12-01
- First posted
- 2009-10-27
- Last updated
- 2014-09-03
Locations
4 sites across 1 country: China
Source: ClinicalTrials.gov record NCT01002092. Inclusion in this directory is not an endorsement.